The Center for Biosimilars® recaps the top news for the week of February 25, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 25.
Number 5: New psoriasis treatment guidelines say that anti—tumor necrosis factor biosimilars can be considered therapeutically interchangeable with their reference products.
Number 4: A newly published paper looks ahead to the potential for—and challenges related to—biosimilars of products like gene and cell therapies.
Number 3: As part of its investigation into drug pricing, the Senate Finance Committee is launching a bipartisan probe into insulin prices.
Number 2: Sandoz has filed suit against Amgen, asking the court for a declaratory judgment of patent noninfringement and invalidity.
Number 1: A judge has directed Boehringer Ingelheim to disclose its launch plans for its biosimilar adalimumab as part of a long-running patent dispute with AbbVie.
Finally, last week, our e-newsletter asked which stakeholder group you think has the most influence in combatting misinformation on biosimlars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.